MO44-4 Phase II study of nivolumab rechallenge in advanced NSCLC pts who responded to prior anti-PD-1/L1 inhibitors; WJOG 9616LSatoru Miura,Hiroaki Akamatsu,Shunsuke Teraoka,Shinkichi Takamori,Hidetoshi Hayashi,Akito Hata,Yukihiro Toi,Yoshimasa Shiraishi,Nobuaki Mamesaya,Yuki Sato,Naoki Furuya,Yasuhiro Koh,Toshihiro Misumi,Nobuyuki Yamamoto,Kazuhiko NakagawaAnnals of Oncology(2022)引用 0|浏览13暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要